User profiles for Derek R. Johnson
 | Derek JohnsonWest Virginia University's CAFEE Verified email at mail.wvu.edu Cited by 678 |
Glioblastoma survival in the United States before and during the temozolomide era
DR Johnson, BP O'Neill - Journal of neuro-oncology, 2012 - Springer
The standard-of-care treatment for newly diagnosed glioblastoma changed in 2005, when
radiation therapy plus temozolomide chemotherapy replaced radiation therapy alone. It is not …
radiation therapy plus temozolomide chemotherapy replaced radiation therapy alone. It is not …
2016 updates to the WHO brain tumor classification system: what the radiologist needs to know
DR Johnson, JB Guerin, C Giannini, JM Morris… - Radiographics, 2017 - pubs.rsna.org
Radiologists play a key role in brain tumor diagnosis and management and must stay abreast
of developments in the field to advance patient care and communicate with other health …
of developments in the field to advance patient care and communicate with other health …
Early measures of cognitive function predict survival in patients with newly diagnosed glioblastoma
DR Johnson, AM Sawyer, CA Meyers… - Neuro …, 2012 - academic.oup.com
Cognitive dysfunction is a common manifestation of primary brain tumors. We evaluated the
association between early cognitive dysfunction and prognosis in a cohort of patients with …
association between early cognitive dysfunction and prognosis in a cohort of patients with …
Pilocytic astrocytoma survival in adults: analysis of the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute
DR Johnson, PD Brown, E Galanis… - Journal of neuro …, 2012 - Springer
Pilocytic astrocytoma is a WHO grade 1 brain tumor common in children. Relatively little is
known about the behavior of pilocytic astrocytomas in adult patients, largely due to the rarity of …
known about the behavior of pilocytic astrocytomas in adult patients, largely due to the rarity of …
Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: A population‐based analysis
DR Johnson, HE Leeper, JH Uhm - Cancer, 2013 - Wiley Online Library
BACKGROUND Bevacizumab received US Food and Drug Administration approval for use
in recurrent glioblastoma based on promising radiographic response data, but without clear …
in recurrent glioblastoma based on promising radiographic response data, but without clear …
Conditional probability of long‐term survival in glioblastoma: a population‐based analysis
DR Johnson, DJ Ma, JC Buckner, JE Hammack - Cancer, 2012 - Wiley Online Library
BACKGROUND: Advances in glioblastoma care have resulted in a larger proportion of patients
surviving beyond 2 years after diagnosis. It is not clear how long‐term survivors should …
surviving beyond 2 years after diagnosis. It is not clear how long‐term survivors should …
Near-field characterization of methane emission variability from a compressor station using a model aircraft
…, L Tao, DJ Lary, DR Johnson… - … science & technology, 2015 - ACS Publications
A model aircraft equipped with a custom laser-based, open-path methane sensor was
deployed around a natural gas compressor station to quantify the methane leak rate and its …
deployed around a natural gas compressor station to quantify the methane leak rate and its …
“Real world” use of a highly reliable imaging sign:“T2-FLAIR mismatch” for identification of IDH mutant astrocytomas
R Jain, DR Johnson, SH Patel, M Castillo… - Neuro …, 2020 - academic.oup.com
AbstractThe T2-FLAIR (fluid attenuated inversion recovery) mismatch sign is an easily
detectable imaging sign on routine clinical MRI studies that suggests diagnosis of isocitrate …
detectable imaging sign on routine clinical MRI studies that suggests diagnosis of isocitrate …
The John Insall Award: control-matched evaluation of painful patellar Crepitus after total knee arthroplasty
DA Dennis, RH Kim, DR Johnson… - Clinical Orthopaedics …, 2011 - journals.lww.com
… MD 1 ; Johnson, Derek R. MD 5 ; Springer, Bryan D. MD 6 ; Fehring, Thomas K. … Clarke, HD.,
Fuchs, R., Scuderi, GR., Mills, EL., Scott, WN. and Insall, JN. The influence of femoral component …
Fuchs, R., Scuderi, GR., Mills, EL., Scott, WN. and Insall, JN. The influence of femoral component …
Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma
DR Johnson, DW Kimmel, PA Burch… - Neuro …, 2011 - academic.oup.com
The objective of this phase II study was to evaluate the efficacy and safety of subcutaneous
octreotide therapy for the treatment of recurrent meningioma and meningeal …
octreotide therapy for the treatment of recurrent meningioma and meningeal …